1349.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 17:08):

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...

Stats
本日の出来高	1.37M
平均出来高	677 413
時価総額	704.16M
EPS	HKD0.0500 ( 2020-09-30 )
Last Dividend	HKD0.0798 ( 2023-06-05 )
Next Dividend	HKD0 ( N/A )
P/E	19.64
ATR14	HKD0.00800 (0.37%)

FUDANZHANGJIANG 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

FUDANZHANGJIANG 相関 - 通貨/商品

-0.31
( neutral )

-0.48
( neutral )

-0.54
( weak negative )

-0.06
( neutral )

-0.50
( weak negative )

FUDANZHANGJIANG 財務諸表

Annual	2023
収益:	HKD850.73M
総利益:	HKD776.66M (91.29 %)
EPS:	HKD0.110

FY	2023
収益:	HKD850.73M
総利益:	HKD776.66M (91.29 %)
EPS:	HKD0.110

FY	2022
収益:	HKD1.03B
総利益:	HKD947.10M (91.85 %)
EPS:	HKD0.130

FY	2021
収益:	HKD1.14B
総利益:	HKD1.06B (92.90 %)
EPS:	HKD0.210

Financial Reports:

No articles found.

FUDANZHANGJIANG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0859 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0798 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

FUDANZHANGJIANG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 2.11 - Decrease likely (57.72%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0623	2015-06-04
Last Dividend	HKD0.0798	2023-06-05
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	9	--
Total Paid Out	HKD0.566	--
Avg. Dividend % Per Year	0.00%	--
Score	2.49	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	2.11
Div. Directional Score	6.35	--

Next Divdend (Est)
(2025-04-07)

HKD0.0845 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.49

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3996.HK	Ex Dividend Junior	2023-05-15	Annually	0.00%
1809.HK	Ex Dividend Knight	2023-05-24	Annually	0.00%
0838.HK	Ex Dividend Junior	2023-09-07	Annually	0.00%
0002.HK	Ex Dividend Knight	2023-09-04	Quarterly	0.00%
2386.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
1375.HK	Ex Dividend Junior	2023-06-09	Annually	0.00%
0436.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
6818.HK	Ex Dividend Junior	2023-06-26	Annually	0.00%
1921.HK	Ex Dividend Junior	2023-05-25	Sporadic	0.00%
0954.HK	No Dividend Player	2023-05-22	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.128	1.500	7.45	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0378	1.200	8.74	10.00	[0 - 0.3]
returnOnEquityTTM	0.0468	1.500	-0.591	-0.886	[0.1 - 1]
payoutRatioTTM	0.701	-1.000	2.99	-2.99	[0 - 1]
currentRatioTTM	3.70	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.60	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.37	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00381	-1.500	9.94	-10.00	[0 - 0.6]
interestCoverageTTM	87.71	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.0623	2.00	9.98	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0245	2.00	-0.0123	-0.0245	[0 - 20]
debtEquityRatioTTM	0.00465	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.911	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.0889	1.000	-0.222	-0.222	[0.1 - 0.6]
cashFlowToDebtRatioTTM	6.48	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.296	0.800	-1.362	-1.089	[0.5 - 2]
Total Score				10.58

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	20.45	1.000	8.04	0	[1 - 100]
returnOnEquityTTM	0.0468	2.50	-0.380	-0.886	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0245	2.00	-0.00817	-0.0245	[0 - 30]
dividendYielPercentageTTM	4.09	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0623	2.00	9.98	10.00	[0 - 30]
payoutRatioTTM	0.701	1.500	2.99	-2.99	[0 - 1]
pegRatioTTM	-0.708	1.500	-8.06	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0835	1.000	-0.413	0	[0.1 - 0.5]
Total Score				2.11

FUDANZHANGJIANG

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.